Abstract:

Objective   To evaluate the antibody response and influencing factors after revaccination with 3 doses of 4 types of hepatitis B vaccines among low-response adults.  Methods   The adults aged from 18 to 49 years old who were low response to the primary hepatitis B vaccine were randomly divided into 4 groups and revaccinated with one of the following types of hepatitis B vaccines at 0-1-6 schedule respectively: 10μg hepatitis B vaccine made by recombinant deoxyribonucleic acid techniques in Saccharomyces Cerevisiae (HepB-SC), 20μg HepB-SC, 10μg hepatitis B vaccine made by recombinant deoxyribonucleic acid techniques in Hansenula Polymorpha (HepBHP) and 20μg hepatitis B vaccine made by Chinese hamster ovary cell (HepB-CHO).  Questionnaire survey was made and blood samples were drawn from each person one month after the third dose. Hepatitis B virus surface antigen (Anti-HBs) were detected by the CMIA method. Influencing factors on antibody response were compared and analyzed by the multiple regression analysis.  Results   The total rate of anti-HBs seroconversion was 78.25%. The rates of anti-HBs seroconversion were 70.18%, 78.79%, 77.34% and 84.62% in the 10μg HepB-SC group, the 10μg HepB-HP group, the 20μg HepB-SC group and the 20μg HepB-CHO group respectively and the difference was statistically significant(P=0.004). The total corresponding geometric mean concentration (GMC) of anti-HBs was 443.92mIU/mL. The GMCs of anti-HBs of 4 groups were 297.03mIU/mL, 435.21mIU/mL, 445.76mIU/mL and 604.64mIU/mL. The GMCs were also significantly different by the groups(P<0.001). The multivariate analysis showed that the antibody level and the vaccine type for the primary immunization, and the vaccine type for the revaccination were related to the antibody response after the revaccination.  Conclusion   A good antibody response could be achieved by revaccination with 3 doses of hepatitis B among the low-response adults. The antibody response of 20μg HepB-CHO is better than 10μg HepB-SC.

Key words: Adult; Hepatitis B vaccine; Low-respond; Revaccination